DOCSLIB.ORG

Graphical Abstracts Current Cancer Drug Targets, 2016, Vol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Graphical Abstracts Current Cancer Drug Targets, 2016, Vol Graphical Abstracts Current Cancer Drug Targets, 2016, Vol. 16, No. 2 i Graphical AbstractV Current Cancer Drug Targets, 2016, Vol. 16, No. 2 101 Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response Takayo Fukuda, Tomoko Tsuruga, Takako Kuroda, Hiroyuki Nishikawa and Tomohiko Ohta* *Department of Translational Oncology, Institute of Advanced Medical Science, St. Marianna University Graduate School of Medicine, Kawasaki, 216-8511, Japan PRC1 BRCA1/BARD1 RING RING RNF2/BMI1 BRCA1/BARD1 CBX CBX2, 4, 6, 7, 8 CBX1, 3, 5 me H2A C-terminus me H3K27 H3K9 ASXL1 PR-DUB BAP1 Current Cancer Drug Targets, 2016, Vol. 16, No. 2 110 Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer Yasumichi Inoue*, Yuka Itoh, Koichi Sato, Fumihiro Kawasaki, Chihiro Sumita, Takahito Tanaka, Daisuke Morishita and Hidetoshi Hayashi* *Department of Cell Signaling, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe- dori, Mizuho-ku, Nagoya 467-8603, Japan Current Cancer Drug Targets, 2016, Vol. 16, No. 2 119 The SCF-type E3 Ubiquitin Ligases as Cancer Targets Kyoko Kitagawa and Masatoshi Kitagawa* *Department of Molecular Biology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan E1 E2 Ub 㻌 Ub Rbx1 Ub Cul1 Ub Ub Skp1 Substrate F-box protein F-box SCF-type E3 ligase defect stabilization in cancer in cancer oncogenic Fbw7 proteins c-myc, Notch, c-Jun, Cyc E etc overexpression destabilization in cancer in cancer anti-oncogenic Skp2 proteins p27, p21, p57, p130 etc ii Current Cancer Drug Targets, 2016, Vol. 16, No. 2 Graphical Abstracts Current Cancer Drug Targets, 2016, Vol. 16, No. 2 130 E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers Kazuma Masumoto* and Masatoshi Kitagawa *Department of Oral and Maxillofacial Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan Oncogenic E3s Tumor suppressive substrates Tumor suppressive E3s Oncogenic substrates Oral carcinogenesis Current Cancer Drug Targets, 2016, Vol. 16, No. 2 136 Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito* *Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan Ubiquitylation E2 Proteasomal degradation of target proteins Target Protein Ubiquitin Ligase Ligand for Ligand for Target Protein Ubiquitin Ligase Hybrid Molecule (SNIPER and PROTAC) Current Cancer Drug Targets, 2016, Vol. 16, No. 2 147 Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin- Proteasome System in Cancer Development Satoshi Sakai*, Chiharu Miyajima, Chiharu Uchida, Yuka Itoh, Hidetoshi Hayashi and Yasumichi Inoue *Department of Molecular Biology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3125, Japan MAPK activation, Wnt signal, hypoxia, ER stress, Dysregulation of E3 ligases etc. E3 ubiquitin ligase Ub Ub TRBs Ub Ub substrate substrate (C/EBPD etc) TRBs cancer progresssion Graphical Abstracts Current Cancer Drug Targets, 2016, Vol. 16, No. 2 iii Current Cancer Drug Targets, 2016, Vol. 16, No. 2 157 RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer Chiharu Uchida* and Masatoshi Kitagawa *Research Equipment Center, Hamamatsu University School of Medicine, Hamamatsu, Japan Normal cell function Ub Ub Ub E2 E2 E2 Ub Ub RING E3 HECT E3 RBR E3 Ub Ub Ub substrate substrate substrate Deregulated ubiquitylation E3-substrate binding inhibitors Aberrant function E3 activity inhibitors Cancer Current Cancer Drug Targets, 2016, Vol. 16, No. 2 175 Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment Erika Giordani, Federica Zoratto, Martina Strudel, Anselmo Papa*, Luigi Rossi, Marina Minozzi, Davide Caruso, Eleonora Zaccarelli, Monica Verrico and Silverio Tomao *Department of Medico-Surgical Sciences and Biotechnologies, “Sapienza” University of Rome; Oncology Unit, ICOT, Via Faggiana 1668, 04100 Latina, Italy Current Cancer Drug Targets, 2016, Vol. 16, No. 2 186 Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition Tiziana Guarnieri* *Dept. of Biology, Geology and Environmental Sciences, School of Sciences, Alma Mater Studiorum Università di Bologna, Italy; Center for Applied Biomedical Research (C.R.B.A.), S. Orsola-Malpighi University Hospital, Bologna, Italy; Biostructures and Biosystems National Institute (I.N.B.B.) Interuniversity Consortium, Rome, Italy .
Load more

Recommended publications
  • BAP1: Case Report and Insight Into a Novel Tumor Suppressor Kanad Ghosh1, Badri Modi2, William D
    Ghosh et al. BMC Dermatology (2017) 17:13 DOI 10.1186/s12895-017-0065-6 CASEREPORT Open Access BAP1: case report and insight into a novel tumor suppressor Kanad Ghosh1, Badri Modi2, William D. James2 and Brian C. Capell1,2,3* Abstract Background: BRCA1-Associated-Protein 1 (BAP1) is a dynamic tumor suppressor which, when mutated, has been associated with an increased risk of uveal melanoma, cutaneous melanoma, mesothelioma, and several other cancers. Germline BAP1 mutations have been extensively studied, where they have been found to cause hereditary cancer susceptibility. However, their sporadic counterparts, tumors that display a loss of BAP1 expression due to somatically arising mutations in the BAP1 gene, remain a poorly described entity. Case presentation: Here we present the case of a 49-year-old female who presented with an asymptomatic dome-shaped pink papule on the dorsal foot which was found on biopsy to be deficient in the BAP1 tumor suppressor. While the patient’s family history did not suggest the presence of a familial cancer syndrome, germline genetic testing was performed and was negative. The patient underwent surgical excision of this sporadically appearing “BAPoma” by Mohs surgery. Conclusions: Given the relatively banal clinical appearance of these dome-shaped neoplasms, sporadic BAPomas may often be overlooked by clinicians and dermatologists. In addition to providing a representative case, here we also provide a synopsis of the current understanding of these neoplasms, both in terms of the histopathological features, as well as the molecular mechanisms underlying BAP1 function and its ability to prevent tumorigenesis. Keywords: BAP1, Tumor suppression, Familial cancer syndrome Background More recently, sporadic somatic BAP1 mutations have Within the last decade, the BRCA1-Associated-Protein 1 been shown to occur in the setting of both mesothelioma (BAP1) has been increasingly appreciated for its tumor sup- and uveal melanoma [3].
    [Show full text]
  • Genitourinary Pathology (Including Renal Tumors)
    LABORATORY INVESTIGATION THE BASIC AND TRANSLATIONAL PATHOLOGY RESEARCH JOURNAL LI VOLUME 99 | SUPPLEMENT 1 | MARCH 2019 2019 ABSTRACTS GENITOURINARY PATHOLOGY (INCLUDING RENAL TUMORS) (776-992) MARCH 16-21, 2019 PLATF OR M & 2 01 9 ABSTRACTS P OSTER PRESENTATI ONS EDUCATI ON C O M MITTEE Jason L. Hornick , C h air Ja mes R. Cook R h o n d a K. Y a nti s s, Chair, Abstract Revie w Board S ar a h M. Dr y and Assign ment Co m mittee Willi a m C. F a q ui n Laura W. La mps , Chair, C ME Subco m mittee C ar ol F. F ar v er St e v e n D. Billi n g s , Interactive Microscopy Subco m mittee Y uri F e d ori w Shree G. Shar ma , Infor matics Subco m mittee Meera R. Ha meed R aj a R. S e et h al a , Short Course Coordinator Mi c h ell e S. Hir s c h Il a n W ei nr e b , Subco m mittee for Unique Live Course Offerings Laksh mi Priya Kunju D a vi d B. K a mi n s k y ( Ex- Of ici o) A n n a M ari e M ulli g a n Aleodor ( Doru) Andea Ri s h P ai Zubair Baloch Vi nita Parkas h Olca Bast urk A nil P ar w a ni Gregory R. Bean , Pat h ol o gist-i n- Trai ni n g D e e p a P atil D a ni el J.
    [Show full text]
  • Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric
    Author Manuscript Published OnlineFirst on December 28, 2017; DOI: 10.1158/0008-5472.CAN-17-2876 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains Hongzhuang Peng1, Jeremy Prokop2, Jayashree Karar1, Kyewon Park1, Li Cao3, J. William Harbour4, Anne M. Bowcock5, S. Bruce Malkowicz6, Mitchell Cheung7, Joseph R. Testa7, and Frank J. Rauscher, 3rd1 1Wistar Institute, Philadelphia, PA, USA; 2HudsonAlpha Genome Sequencing Center, Huntsville AL, USA; 3Washington University in St Louis, St. Louis, MO; 4University of Miami School of Medicine, Miami, FL, USA; 5Icahn School of Medicine at Mount Sinai, New York, NY; 6University of Pennsylvania and Veterans Affairs Medical Center Philadelphia, Philadelphia PA, USA; 7Fox Chase Cancer Center, Philadelphia, PA, USA Running Title: BAP1 mutations disable ASXL1/2’s regulation of BAP1 activity Key Words: BAP1, PR-DUB, ASXL1/2, mutations, deubiquitinase, cancer, tumor susceptibility Correspondence: Frank J. Rauscher, 3rd, Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104; Phone: 215-898-0995; Fax: 215-898-3929; E-mail: [email protected]; Joseph R. Testa, 5Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA; Phone: 215-728- 2610; Fax: 215-214-1623; E-mail: [email protected] Précis: Combined computational and biochemical approaches demonstrate that the BAP1- ASXL2 interaction is direct and high affinity and that many BAP1 mutations act allosterically to inhibit BAP1-ASXL2 binding. 1 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 28, 2017; DOI: 10.1158/0008-5472.CAN-17-2876 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • Prognostic Value of Chromosomal Imbalances, Gene Mutations, and BAP1
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio istituzionale della ricerca - Università di Genova Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in Uveal Melanoma. Serena Patrone1*, Irena Maric2,3*, Mariangela Rutigliani4, Francesco Lanza5, Matteo Puntoni6, Barbara Banelli7, Silvia Rancati2, Giovanna Angelini8,, Adriana Amaro8, Paolo Ligorio5, Carlotta Defferrari9, Mauro Castagnetta10, Roberto Bandelloni4, Carlo Mosci5, Andrea DeCensi9, Massimo Romani7, Urlich Pfeffer8, Silvia Viaggi2,10, §, and Domenico A. Coviello10 Department of Internal Medicine (DIMI)1, Department of Earth Sciences, Environment, and Life, Università Degli Studi di Genova, Genova (DISTAV)2, University of Genoa, Genova, Italy; Biotherapy3, Tumor Epigenetics Uni7, Molecular Pathology Unit8, Ospedale Policlinico San Martino, Genova, Italy; Pathology Unit4, Ocular Oncology Unit5, Clinical Trial Unit/Scientific Direction6, Medical Oncology Unit9, Human Genetics Laboratory10, E.O. Ospedali Galliera, Genova, Italy. died April 25, 2017 Key words: Genetic profile, BAP1 expression, uveal melanoma progression. * These authors equally contributed to the work § Corresponding author §Silvia Viaggi DISTAV University of Genoa Human Genetics Laboratory, E.O. Ospedali Galliera Via Volta, 6 I-16128 Genova [email protected] tel. 0039 0105634362 FAX 0039 010-57481384 1 ABSTRACT Uveal melanoma (UM) exhibits recurring chromosomal abnormalities and gene driver mutations, which are related to tumor evolution/progression. Almost half of the patients with UM develop distant metastases, predominantly to the liver, and so far there are no effective adjuvant therapies. An accurate UM genetic profile could assess the individual patient’s metastatic risk, and provide the basis to determine an individualized targeted therapeutic strategy for each UM patients.
    [Show full text]
  • ASXL3 Bridges BRD4 to BAP1 Complex and Governs Enhancer
    Szczepanski et al. Genome Medicine (2020) 12:63 https://doi.org/10.1186/s13073-020-00760-3 RESEARCH Open Access ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer Aileen Patricia Szczepanski1,2†, Zibo Zhao1,2†, Tori Sosnowski3, Young Ah Goo1,2,3, Elizabeth Thomas Bartom1,2 and Lu Wang1,2* Abstract Background: Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer that often results in rapid tumor growth, early metastasis, and acquired therapeutic resistance. Consequently, such phenotypical characteristics of SCLC set limitations on viable procedural options, making it difficult to develop both screenings and effective treatments. In this study, we examine a novel mechanistic insight in SCLC cells that could potentially provide a more sensitive therapeutic alternative for SCLC patients. Methods: Biochemistry studies, including size exclusion chromatography, mass spectrometry, and western blot analysis, were conducted to determine the protein-protein interaction between additional sex combs-like protein 3 (ASXL3) and bromodomain-containing protein 4 (BRD4). Genomic studies, including chromatin immunoprecipitation sequencing (ChIP-seq), RNA sequencing, and genome-wide analysis, were performed in both human and mouse SCLC cells to determine the dynamic relationship between BRD4/ASXL3/BAP1 epigenetic axis in chromatin binding and its effects on transcriptional activity. Results: We report a critical link between BAP1 complex and BRD4, which is bridged by the physical interaction between ASXL3 and BRD4 in an SCLC subtype (SCLC-A), which expresses a high level of ASCL1. We further showed that ASXL3 functions as an adaptor protein, which directly interacts with BRD4’s extra-terminal (ET) domain via a novel BRD4 binding motif (BBM), and maintains chromatin occupancy of BRD4 to active enhancers.
    [Show full text]
  • Role of the Bap1/Asxl1 Complex in Malignant Transformation and Therapeutic Response
    ROLE OF THE BAP1/ASXL1 COMPLEX IN MALIGNANT TRANSFORMATION AND THERAPEUTIC RESPONSE by Lindsay Marie LaFave A Dissertation Presented to the Faculty of the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy New York, NY July, 2015 ____________________________ ______________________ Ross L. Levine, MD Date Dissertation Mentor © 2015 Lindsay Marie LaFave DEDICATION To my parents, without your endless support and dedication none of this would have been possible. To my sister, for being the very best of friends and always making me laugh To my loving husband, for the constant happiness you bring me. You are my everything. iii ABSTRACT Role of the BAP1/ASXL1 Complex in Malignant Transformation and Therapeutic Response Somatic mutations in epigenetic modifiers have recently been identified in hematopoietic malignancies and in other human cancers. However, the mechanisms by which these epigenetic mutations lead to changes in gene expression and disease transformation have not yet been well delineated. Epigenetic modifiers include chromatin regulators that modify post-translational modifications on histone molecules. Mutations in ASXL1 (Addition of sex combs-like 1) are a common genetic event in a spectrum of myeloid malignancies and are associated with poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We investigated the role of ASXL1 mutations on target gene expression and chromatin state in hematopoietic cell lines and mouse models. We performed loss-of-function in vitro experiments in AML cell lines and conducted expression analysis. Loss of ASXL1 resulted in increased expression of the posterior HOXA cluster.
    [Show full text]
  • Families with BAP1-Tumor Predisposition Syndrome in the Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines
    cancers Article Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines Cindy Chau 1 , Remco van Doorn 2, Natasha M. van Poppelen 3,4, Nienke van der Stoep 5, Arjen R. Mensenkamp 6 , Rolf H. Sijmons 7, Barbara W. van Paassen 3, Ans M. W. van den Ouweland 3, Nicole C. Naus 4, Annemieke H. van der Hout 7, Thomas P. Potjer 5, Fonnet E. Bleeker 8, Marijke R. Wevers 6, Liselotte P. van Hest 9, Marjolijn C. J. Jongmans 6,10, Marina Marinkovic 1, Jaco C. Bleeker 1, Martine J. Jager 1 , Gregorius P. M. Luyten 1 and Maartje Nielsen 5,* 1 Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 2 Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 3 Department of Clinical Genetics, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands 4 Department of Ophthalmology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands 5 Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 6 Department of Clinical Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands 7 Department of Genetics, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands 8 Department of Clinical Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands 9 Department of Clinical Genetics, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands 10 Department of Clinical Genetics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands * Correspondence: [email protected] Received: 30 June 2019; Accepted: 1 August 2019; Published: 4 August 2019 Abstract: Germline pathogenic variants in the BRCA1-associated protein-1 (BAP1) gene cause the BAP1-tumor predisposition syndrome (BAP1-TPDS, OMIM 614327).
    [Show full text]
  • The Distinct Biological Implications of Asxl1 Mutation and Its Roles In
    Hsu et al. Journal of Hematology & Oncology (2017) 10:139 DOI 10.1186/s13045-017-0508-x RESEARCH Open Access The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model Yueh-Chwen Hsu1, Yu-Chiao Chiu2, Chien-Chin Lin1,3, Yuan-Yeh Kuo4, Hsin-An Hou5, Yi-Shiuan Tzeng4, Chein-Jun Kao3, Po-Han Chuang3, Mei-Hsuan Tseng5, Tzu-Hung Hsiao2, Wen-Chien Chou1,3,5* and Hwei-Fang Tien5* Abstract Background: Additional sex combs-like 1 (ASXL1) is frequently mutated in myeloid malignancies. Recent studies showed that hematopoietic-specific deletion of Asxl1 or overexpression of mutant ASXL1 resulted in myelodysplasia- like disease in mice. However, actual effects of a “physiological” dose of mutant ASXL1 remain unexplored. Methods: We established a knock-in mouse model bearing the most frequent Asxl1 mutation and studied its pathophysiological effects on mouse hematopoietic system. Results: Heterozygotes (Asxl1tm/+) marrow cells had higher in vitro proliferation capacities as shown by more colonies in cobblestone-area forming assays and by serial re-plating assays. On the other hand, donor hematopoietic cells from Asxl1tm/+ mice declined faster in recipients during transplantation assays, suggesting compromised long-term in vivo repopulation abilities. There were no obvious blood diseases in mutant mice throughout their life-span, indicating Asxl1 mutation alone was not sufficient for leukemogenesis. However, this mutation facilitated engraftment of bone marrow cell overexpressing MN1. Analyses of global gene expression profiles of ASXL1-mutated versus wild-type human leukemia cells as well as heterozygote versus wild-type mouse marrow precursor cells, with or without MN1 overexpression, highlighted the association of in vivo Asxl1 mutation to the expression of hypoxia, multipotent progenitors, hematopoietic stem cells, KRAS, and MEK gene sets.
    [Show full text]
  • The BAP1 Deubiquitinase Complex Is a General Transcriptional Co-Activator
    bioRxiv preprint doi: https://doi.org/10.1101/244152; this version posted January 8, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The BAP1 deubiquitinase complex is a general transcriptional co-activator Antoine Campagne1,2, Dina Zielinski1,2 ,3, Audrey Michaud1,2, Stéphanie Le Corre1,2, Florent Dingli1, Hong Chen1,2, Ivaylo Vassilev1,2 ,3, Ming-Kang Lee1,2, Nicolas Servant1,3, Damarys Loew1, Eric Pasmant4, Sophie Postel-Vinay5, Michel Wassef1,2* and Raphaël Margueron1,2* 1 Institut Curie, Paris Sciences et Lettres Research University, 75005 Paris, France. 2 INSERM U934/ CNRS UMR3215. 3 INSERM U900, Mines ParisTech. 4 EA7331, Faculty of Pharmacy, University of Paris Paris Descartes, Department of Molecular Genetics Pathology, Cochin Hospital, HUPC AP-HP, Paris, France. 5 Gustave Roussy, Département d'Innovation Thérapeutique et Essais Précoces, INSERM U981, Université Paris-Saclay, Villejuif, F-94805, France. *Corresponding Authors: Institut Curie - 26 rue d'Ulm, 75005 Paris Emails: [email protected] or [email protected] Tel: +33 (0)156246551 Fax: +33 (0)156246939 bioRxiv preprint doi: https://doi.org/10.1101/244152; this version posted January 8, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT In Drosophila, a complex consisting of Calypso and ASX catalyzes H2A deubiquitination and has been reported to act as part of the Polycomb machinery in transcriptional silencing. The mammalian homologs of these proteins (BAP1 and ASXL1/2/3, respectively), are frequently mutated in various cancer types, yet their precise functions remain unclear.
    [Show full text]
  • MECHANISMS of TRAIL RESISTANCE Neelam Kumar
    MECHANISMS OF TRAIL RESISTANCE Neelam Kumar University College London A thesis submitted for the degree of Doctor of Philosophy 2018 1 DECLARATION I, Neelam Kumar, confirm that the work presented in this thesis is my own. Where information has been derived from other sources I confirm that this has been indicated and acknowledged in the thesis. 2 ABSTRACT Malignant pleural mesothelioma (MPM) is a devastating disease for which limited effective therapies are currently available. Tumour necrosis factor- related apoptosis-inducing ligand (TRAIL) and other death receptor (DR) agonists are pro-apoptotic agents that trigger the extrinsic apoptotic pathway selectively in cancer cells. Previous work has shown that supports that loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) augments sensitivity to recombinant TRAIL (rTRAIL) in MPM cells. This study shows that BAP1 is a candidate biomarker for rTRAIL sensitivity in cell line, early passage culture and tumour explant models of MPM. In addition, BAP1 is a potential biomarker for sensitivity to other DR agonists and for additional cancer types with BAP1 mutations. I have also identified other novel candidate biomarkers for DR agonist sensitivity, notably ASXL1/2, through exploration of the mechanism underlying the BAP1-rTRAIL association. I present data supporting the clinical relevance and utility of the BAP1-TRAIL association. I have shown that loss of BAP1 function occurs in a significant proportion of MPM tumours in the UK and that loss of BAP1 function augments sensitivity to TRAIL in primary tumour tissue. I describe in vitro data supporting the hypothesis that loss of BAP1 function augments sensitivity to rTRAIL in MPM.
    [Show full text]
  • BAP1 Constrains Pervasive H2ak119ub1 to Control the Transcriptional Potential of the Genome
    Downloaded from genesdev.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press BAP1 constrains pervasive H2AK119ub1 to control the transcriptional potential of the genome Nadezda A. Fursova, Anne H. Turberfield, Neil P. Blackledge, Emma L. Findlater, Anna Lastuvkova, Miles K. Huseyin, Paula Dobrinic,́ and Robert J. Klose Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom Histone-modifying systems play fundamental roles in gene regulation and the development of multicellular organisms. Histone modifications that are enriched at gene regulatory elements have been heavily studied, but the function of modifications found more broadly throughout the genome remains poorly understood. This is exem- plified by histone H2A monoubiquitylation (H2AK119ub1), which is enriched at Polycomb-repressed gene pro- moters but also covers the genome at lower levels. Here, using inducible genetic perturbations and quantitative genomics, we found that the BAP1 deubiquitylase plays an essential role in constraining H2AK119ub1 throughout the genome. Removal of BAP1 leads to pervasive genome-wide accumulation of H2AK119ub1, which causes widespread reductions in gene expression. We show that elevated H2AK119ub1 preferentially counteracts Ser5 phosphorylation on the C-terminal domain of RNA polymerase II at gene regulatory elements and causes reductions in transcription and transcription-associated histone modifications. Furthermore, failure to constrain pervasive H2AK119ub1 compromises Polycomb complex occupancy at a subset of Polycomb target genes, which leads to their derepression, providing a potential molecular rationale for why the BAP1 ortholog in Drosophila has been charac- terized as a Polycomb group gene. Together, these observations reveal that the transcriptional potential of the genome can be modulated by regulating the levels of a pervasive histone modification.
    [Show full text]